In prostate cancer patient-derived xenograft (PDX) models, the combined inhibition of TMEM16A and TRPV1 results in a 63% reduction in MMP-9-positive cells at the tumor invasive front, surpassing the efficacy of single-agent treatments (Zheng et al., [64]). Here, ANO1 is linked to prostate cancer.